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BRCA1/BRCA2 mutations account for a substantial proportion of familial breast cancer, but clearly mutations in additional genes exist,
one candidate being the p53 gene. To evaluate its putative involvement in inherited predisposition to breast/ovarian cancer in Jewish
high-risk women, mutational analysis of the p53 gene (exons 4–9) was carried out using exon-specific polymerase chain reaction
followed by denaturing gradient gel electrophoresis (DGGE) analysis, complemented by DNA sequencing of abnormally migrating
fragments. Overall, 132 Jewish breast cancer patient non-BRCA1/2 mutation carriers and 167 average risk controls (Ashkenazi
(n¼60), non-Ashkenazi (n¼107)) were genotyped, and no inactivating p53 germline mutations were detected. Consistent
migration abnormalities were noted in 167 fragments, 134 of which were shown to be the Arg72Pro polymorphism, whereas
migration abnormalities in fragments containing exons 4 (n¼2) and 6 (n¼23) and introns 3 (n¼4) and 9 (n¼4) corresponded to
five previously described polymorphisms. Allele distribution of the R72P missense mutation between ethnically diverse Jewish breast
cancer cases and average risk controls showed significant differences: among non-Ashkenazi breast cancer cases, 62.5%, 33.3% and
4.2% were homozygous, heterozygous and homozygous for the Arg72, Arg72Pro and the Pro72 polymorphism, respectively,
whereas for controls, the distribution was 22.4%, 65.4% and 12.2%, respectively (P¼0.00052), and among Ashkenazi breast cancer
cases, allele distribution was 68.5%, 29.6% and 1.9%, whereas for controls, the distribution was 50%, 40% and 10%, respectively
(P¼0.0125). We conclude that arginine homozygosity at codon 72 of the p53 gene is associated with a significant increased breast
cancer risk in Jewish high-risk population.
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Germline mutations in the BRCA1 (MIM#113705) and BRCA2
(MIM#600185) genes account for genetic predisposition and
increased risk for breast and ovarian cancer in the majority of
families with inherited predisposition to both these neoplasms and
in 20–40% of families with site-specific breast cancer (Hall et al,
1990; Easton et al, 1993; Frank et al, 1998). In the majority of high-
risk families of different ethnicities, germline mutations are
scattered throughout both genes and are family specific (BIC
database). In Jewish individuals, only a handful of recurring
mutations have been described in high-risk families (Ganguly et al,
1997; Shiri-Sverdlov et al, 2000). Notably, among Ashkenazim
(East European ancestry), three mutations in BRCA1 (185delAG,
5382InsC) and BRCA2 (6174delT) predominate, and can be
detected in more than 80% of familial breast and ovarian cancer,
in about 40–50% of site-specific familial breast cancer and in 2.5%
of the general population of this ethnic group (Abeliovich et al,
1997). Among non-Ashkenazi (Sephardic) Jews, the 185delAG and
the Tyr978X BRCA1 and the 8765delAT in BRCA2 mutations can
be detected in high-risk families (Shiri-Sverdlov et al, 2001). Yet, a
substantial proportion of familial breast cancer cases have no
identifiable BRCA1/BRCA2 germline mutations (Tereschenko et al,
2002; Perkowska et al, 2003), and other, yet unidentified genetic
factors underlie these cases (Slattery and Kerber, 1993). One of the
most promising candidates as target for molecular analysis as an
inherited breast cancer predisposition gene is the p53 tumour
suppressor gene: it is frequently somatically mutated in a wide
range of human cancers including breast cancer (Harris and
Hollstein, 1993); germline mutations lead to an increased risk for
developing diverse malignancies, including 25–30% of breast
cancer cases (Bukholm et al, 1997), in the context of Li–Fraumeni
syndrome (LFS) or LFL – Li–Fraumeni-like syndrome (Varley,
2003). In addition, based on its pivotal role in DNA damage repair
and its physical and functional interactions with BRCA1 and
BRCA2 proteins (Storey et al, 1998), p53 seems to be a strong
candidate breast cancer predisposition gene. However, previous
analyses of high-risk families of different ethnic background
yielded a paucity of germline mutations in p53 gene in familial
breast cancer (Zelada-Hedman et al, 1997; Balz et al, 2002).
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seem to cluster to the central region of the gene (exons 5–8)
(Hartmann et al, 1995), there are several missense mutations
within this gene that seem to have a deleterious effect on p53
function (p53 database). Notably, the Pro72 and Arg72 variants
have been reported to differ in functional activity: the Arg72
variant was found to be more susceptible to degradation by the
human papillomavirus (HPV) E6 type 18 protein (Storey et al,
1998), while Pro72 is a stronger inducer of transcription than
Arg72. Additionally, the Arg72 variant suppressed effectively
cellular transformation (Thomas et al, 1999), and was more
efficient than the Pro72 variant at inducing apoptosis (Dumont
et al, 2003).
In the present study, the putative contribution of p53 germline
mutations to inherited predisposition to breast/ovarian cancer was
assessed, initially by genotyping high-risk Jewish individual
noncarriers of the predominant Jewish BRCA1/2 mutations for
p53 germline mutations, and subsequently by comparing the
distribution of the R72P alleles among cases and controls.
MATERIALS AND METHODS
DNA isolation
Genomic DNA was prepared from anticoagulated venous blood
samples, using standard techniques, and using the PUREGene
DNA extraction kit (Gentra Systems Inc., Minneapolis, MN, USA)
and following the manufacturer’s recommended protocol.
Breast cancer cases
Ashkenazi and non-Ashkenazi individuals who were counselled
at the Oncogenetic services of the Sheba and Rambam
Medical Centers were eligible for participation. Their ethnic origin
was determined by an interview, and dating parental origin as far
back as possible by at least three generations. All individuals had
breast cancer and one of the following additional criteria: ovarian
cancer; two first or second degree relatives with one of these
neoplasms at any age; age at onset under 40 for breast cancer,
bilateral breast cancer; cooccurrence of breast and ovarian cancer
in one first-degree relative. The study was approved by the
Institutional review board of both participating medical centers
(Rambam and Sheba) and each participant signed a written,
informed consent. All participants were tested, and found not to
harbour any of the predominant Jewish mutations in BRCA1/
BRCA2 (see below).
Controls
Jewish individuals of diverse ethnic origin who came for genetic
counselling at the Genetics institutes in Sheba and Rambam
Medical Centers served as ‘ethnic controls’. These individuals were
either counselled for prenatal disorders or were counselled as to
their risk for developing cancer, and none was deemed ‘high
cancer risk’ by standard criteria. All tested individuals were
unrelated to each other, had no personal or relevant family history
of breast or ovarian cancer, and their precise ancestry was
confirmed at least three generations back.
Mutation analyses of the predominant Jewish mutations in
BRCA1 and BRCA2
Mutational analyses for the three predominant mutations (185de-
lAG, 5382InsC in BRCA1 and 6174delT in BRCA2) were carried
out by restriction enzyme digest of amplified polymerase
chain reaction (PCR) product. The primers used generated
novel restriction sites that distinguish the mutant from the
wild-type allele. Thus, restriction enzyme digest followed PCR,
and analysis of the digested PCR products on agarose gels was
carried out as described previously (Abeliovich et al, 1997; Rohlfs
et al, 1997). The Tyr978X mutation was detected by a modified
PCR-restriction enzyme digest with EcoRV, as described pre-
viously (Theodor et al, 1998). With each gel, a positive control (i.e.
a known mutation proven by DNA sequencing) was run in an
adjacent lane.
MUTATIONAL ANALYSES OF THE p53 GENE
Polymerase chain reaction
Polymerase chain reactions were performed in a final volume of
50ml containing 3ml template DNA (about 50–100ng), 10pM of
each primer, 200mM of each dNTP, standard PCR buffer (1.5mM
MgCl2), 1U of Taq DNA polymerase. Thermal cycling was
accomplished by PTC-100-60 thermocycler (MJ Research Inc.,
Watertown, MA, USA). The cycling profile included an initial
denaturation at 941C for 5min, followed by 35 cycles of thermal
cycling including 941C for 20s, the designated annealing
temperature (range 52–681C) for 1min, extension at 721C for
20s and a final extension cycle at 721C for 5min.
Denaturing gradient gel electrophoresis (DGGE) and
sequence analysis of the p53 gene
Primer sequences, PCR conditions and DGGE analyses parameters
were carried out under the conditions described previously
(Guldberg et al, 1997). All consistently abnormally migrating
fragments (i.e. repeated abnormalities on three independent PCRs)
were subject to sequence analysis using the big Dye terminator
chemistry and kit (PE Biosystems, Foster City, CA, USA), and
using the ABI Prism 310 semiautomatic DNA sequencer (PE
Biosystems).
Statistical analyses
w
2 was performed in order to evaluate Hardy–Weinberg equili-
brium (HWE) in the control group, alleles’s prevalence in
ethnicities, association genotype/allele–phenotype, Hardy–Wein-
berg deviation (in the patient group), Fisher’s exact test and
Armitage’s trend test (Crow, 2001). Type I error was set at 5%, as is
the accepted practised level.
The websites for checking HWE in the control group, w
2 for
genes and alleles association, HWE by the phenotypic categories in
the patient group and Armitage’s trend test: http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl, http://www.unc.edu/~preacher/chisq/chisq.htm.
RESULTS
Characteristics of breast cancer cases
Overall, 132 Jewish breast cancer patients were analysed: 108 (82%)
patients were of Ashkenazi origin and 24 (18%) were of non-
Ashkenazi origin. Among individuals of Ashkenazi origin, 10
patients presented with bilateral breast cancer (9.25%); age range
at diagnosis of first breast cancer was 23–70 years (46710.1 years
– mean7s.d.); mean age at counselling was 50.2710.8 years; the
interval between date of diagnosis and date of testing was 0.5–27
years (5.3575.8 years).
Among non-Ashkenazi cases (n¼24), three patients presented
with bilateral breast cancer (12.5%), and the age range at diagnosis
of first breast cancer was 26–61 years (42.679.8 years); mean age
range at counselling was 49710.6 years. The interval between date
of diagnosis and date of testing ranged from 0.5 to 33 years
(6.677.6 years).
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Jewish mutations among cases
All cases were tested and found not to be carriers of one of the
predominant mutations in BRCA1 (185delAG, 5382InsC) and
BRCA2 (6174delT). The non-Ashkenazis were also analysed for the
Tyr978X BRCA1 mutation, and none was a carrier.
Controls
The age range among Ashkenazi controls (n¼60) was 27–65 years
(39.378.8 years).
The age range among non-Ashkenazi controls (n¼107) was
21–70 years (34.179.6 years).
Mutational analysis
DGGE analysis of exons 4–9 of the p53 gene revealed consistent
migration abnormalities in 167 fragments; 134 of these fragments
were shown to be the Arg72Pro polymorphism (see below).
Migration abnormalities in other fragments containing exons 4
and 6 and introns 3 and 9 were detected in 2, 23, 4 and 4 patients,
respectively. All abnormally migrating fragments were sequenced
and results showed that all abnormal migration patterns could be
attributed to previously described polymorphisms (Table 1). No
inactivating mutations could be shown in any of the analysed
individuals.
R72P analysis The distribution of the Arg72Pro polymorphism in
cases and controls is presented in Tables 2 and 3. Among cases, no
deviation from the HWE was shown. Allele distribution of the
R72P missense mutation among breast cancer cases (Ashkenazi
and non-Ashkenazi) and average risk controls (Ashkenazi
(n¼60), non-Ashkenazi (n¼107)) showed significant differences:
among non-Ashkenazi cases, 62.5%, 33.3% and 4.2% were
homozygous, heterozygous and homozygous for the Arg72,
Arg72Pro and the Pro72 polymorphisms, respectively, whereas
for controls the distribution was 22.4%, 65.4% and 12.2%,
respectively (P¼0.00052), and among Ashkenazi cases, allele
distribution was 68.5%, 29.6% and 1.9%, whereas for controls, the
distribution was 50%, 40% and 10%, respectively (P¼0.0125)
(Tables 2 and 3).
In Armitage’s trend test, which examines genotype–phenotype
correlation, Arg72 homozygosity was significantly associated with
breast cancer cases for the Ashkenazi subgroup (P¼0.00452) as
well as in the non-Ashkenazi subgroup (P¼0.0075).
Analysis by allele prevalence (A/P) also shows a significant
association between the arginine-bearing allele and high-risk cases
(P¼0.00432 for Ashkenazi origin; P¼0.02412 for non-Ashkenazi
origin).
DISCUSSION
In the present study, no inactivating germline mutations in exons
4–9 of the p53 gene were detected in high-risk Jewish individuals
who are not carriers of any of the predominant Jewish mutations
in BRCA1/BRCA2. Previous analyses of high-risk families of
different ethnic background yielded a paucity of germline
mutations in p53 gene in familial breast cancer: only two
mutations were identified among 237 high-risk Norwegian
individuals (Borresen et al, 1992), one mutation among 126
high-risk American individuals (Sidransky et al, 1992) and one
mutation among 21 families from the UK (Evans et al, 2002).
Similar to the results of the present study, no inactivating p53
germline mutations were found in any of Swedish familial breast
cancer patients (Zelada-Hedman et al, 1997) or in German breast
and/or ovarian cancer families (Balz et al, 2002). Thus, despite
Table 1 Polymorphisms detected in the p53 gene
Ethnic origin Number of cases Exon/intron Sequence alteration Predicted effect on protein
Ashkenazi 2 Exon 4 c.108G4A P36P
Ashkenazi 4 Intron 3 Inv3–29 —
Ashkenazi 5 Exon 6 c.606T4C R202R
Ashkenazi 18 Exon 6 c.639A4G R213R
Ashkenazi 4 Intron 9 Inv9–13 —
Table 2 P53 Arg72Pro polymorphism distribution among non-Ashkenazi Jews, breast cancer cases and controls
Cases Controls
P53 alleles n¼24 % n¼107 % Alleles Genotype Armitage’s trend test
Arg/Arg 15 62.5 24 22.4 P¼0.02412 P¼0.00052 P¼0.00750
Arg/Pro 8 33.3 70 65.4
Pro/Pro 1 4.2 13 12.2
Table 3 P53 Arg72Pro polymorphism distribution among Ashkenazi Jews, breast cancer cases and controls
Cases Controls
P53 alleles n¼108 % n¼60 % Alleles Genotype Armitage’s trend test
Arg/Arg 74 68.5 30 50 P¼0.00432 P¼0.0125 P¼0.00452
Arg/Pro 32 29.6 24 40
Pro/Pro 2 1.9 6 10
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lying inherited breast cancer predisposition, p53 germline muta-
tions probably contribute little to these families, unless it is in the
context of LFS or LFS-like phenotype. It is still possible that
germline sequence alterations in the p53 gene affect breast cancer
risk. Intronic variants within the p53 gene have a functional effect
on p53 protein activity and occur at high frequency in familial
breast cancer cases. Lehman et al (2000) detected an intronic
variant (13964G/C) at a significantly high frequency among
familial breast cancer cases (n¼42), with evidence that this
sequence variant is associated with prolonged in vitro survival in
response to cisplatinum treatment and showed decreased che-
motherapy-induced apoptosis (Lehman et al, 2000). The data
regarding the high rate of this specific polymorphism in high-risk
women could not be reproduced in Australian women (Marsh et al,
2001). In addition, intronic polymorphisms with no known
functional consequences (e.g. intron 3–16bp insertion) were
reported to be over-represented in Swedish (Sjalander et al, 1996)
and German breast cancer-prone families (Wang-Gohrke et al,
1998).
An intriguing finding in the present study is that the
distribution of the R72P missense mutation significantly differs
in affected individuals compared with ethnically matched controls.
Specifically, ethnically diverse Jewish breast cancer individuals are
significantly more likely to be R72 homozygotes, compared with
average risk, unaffected individuals.
The Pro72 and Arg72 p53 gene variants have been reported to
display different functional activities: the Arg72 variant is more
susceptible to degradation by the HPV E6 type 18 protein (Storey
et al, 1998), while Pro72 is a stronger inducer of transcription than
the Arg72 variant. Additionally, the Arg72 variant suppressed
effectively cellular transformation (Thomas et al, 1999), and was
more efficient than the Pro72 variant in inducing apoptosis
(Dumont et al, 2003).
The rate of this sequence variant has also been evaluated in
breast cancer cases in ethnically diverse populations, with
inconsistent results. In line with the findings in the present study,
a significantly higher prevalence of homozygosity for the p53
arginine-bearing allele was observed in Turkish breast cancer
patients compared with controls (Buyru et al, 2003), whereas
among Japanese breast cancer cases, Pro72 homozygosity was
significantly more prevalent than in controls (32% Pro72 in cases
and 40.4% in controls) (Huang et al, 2003). Notably, there was no
evidence of association between p53 codon 72 polymorphism and
breast cancer risk Tunisian (Mabrouk et al, 2003), and Russian
individuals (Suspitsin et al, 2003). In addition, this polymorphic
variant was reported to be associated with breast cancer survival
among English breast cancer patients, but this association lacked
statistical significance in multivariate analysis (Goode et al, 2002).
The limitations of this study should be pointed out. This is a
limited study encompassing only women affected with breast
cancer, counselled and tested in two medical centres in Israel. The
implications to other breast cancer populations, even among
Jewish individuals, are unclear and need to be validated.
Furthermore, the applicability of this finding to average risk
population is unclear and needs to be established.
In conclusion, the contribution of p53 germline mutations to
inherited predisposition to breast cancer by inactivating mutations
seems to be limited in Jewish women. It seems that a common
missense mutation (R72P) confers an increased risk to breast
cancer in familial cases of Jewish origin. The applicability and the
generalisability of this preliminary finding need to be confirmed.
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